Bringing the Oncology Community Together

Multiple Myeloma

Latest Multiple Myeloma Articles View more >>
Anderson on Recent Advances in Multiple Myeloma Drugs
Anderson on Recent Advances in Multiple Myeloma Drugs
Pomalidomide (Pomalyst) rode impressive trial results to accelerated FDA approval this year, and Kenneth Anderson thinks it will prove a valuable new tool in the fight against multiple myeloma
B-Cell Malignancies: Transforming Expectations and Outcomes
B-Cell Malignancies: Transforming Expectations and Outcomes
With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.
Stemline Therapeutics Targets Capacity of Tumors to Adapt and Proliferate
Stemline Therapeutics Targets Capacity of Tumors to Adapt and Proliferate
The investigational cancer medications being developed by Stemline Therapeutics attack only a tiny percentage of all tumor cells. But those few cells—the stem cells that resist most treatment and drive tumor growth—may just be the most important ones.
New Drug Class Shows Activity in Refractory Multiple Myeloma
New Drug Class Shows Activity in Refractory Multiple Myeloma
The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.
Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma
Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma
The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.
Research Spotlight

Project Aims to "Bridge the Gap" From Remission to Cure in Multiple Myeloma

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.

Read more >>>
Publications
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.